Trial Profile
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1029 in Patients With Malignant Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 02 Aug 2023
Price :
$35
*
At a glance
- Drugs Benufutamab (Primary)
- Indications Colorectal cancer; Gastric cancer; Male breast cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer; Urogenital cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Genmab
- 07 Jan 2022 Status changed from recruiting to discontinued as per Sponsor decision.
- 19 Feb 2020 According to Genmab media release, initial data of this trial is anticipated in 2020
- 17 Nov 2019 Planned number of patients changed from 206 to 520.